Rochem International, together with their strategic manufacturing partner, Zhejiang Charioteer Pharmaceutical, are honored to be awarded Accord Healthcare’s API supplier of the year 2020. Charles Dods, Chief Sales Officer of Rochem International, stated “This has been a true team effort […]
“Rochem International Inc. is very pleased to announce the successful FDA inspection of Amicogen (China) Biopharm Co Ltd in March of this year. This was the first FDA inspection of Amicogen and included the APIs Tulathromycin and the Ceftiofur series […]
Rochem International is pleased to announce our continued Exclusive Strategic Partnership with Changzhou Sunlight Pharmaceutical Co., Ltd. (Sunlight). Rochem has been partners with Sunlight for nearly 20 years in the North American market and each has been highly influential in […]
December 2017 – Rochem International is pleased to announce that their strategic manufacturing partner, Shenzhen JYMed Technology Co., Ltd. (JYMed), had a successful FDA inspection in December 2017. In addition to this, JYMed’s Oxytocin Certificate of Suitability (CEP) was recently […]
September 30, 2015 – Rochem International Inc. and Fujian South Pharmaceutical Co. Ltd., (FSP) are pleased to announce that FSP has passed their first U.S. FDA inspection in September, 2015. Rochem has worked closely with Fujian South Pharmaceutical Co. Ltd over the […]
We will get back to you within 24 hours.